Herpes Zoster Incidence High In Solid Organ Transplant Recipients

The incidence is highest among African Americans, heart recipients, and older subjects.

The study, led by Steven A. Pergam, MD, MPH, of Fred Hutchinson Cancer Center in Seattle, included a multicenter cohort of 1,077 patients who received an SOT from January 1995 through December 2007 and follow-up care at a Veteran's Affairs hospital. The group included 500 kidney, 461 liver, and 80 heart transplant patients. Thirty-six patients received other organs.

The overall HZ incidence was 22.2 infections per 1,000 patient-years, according to a report in Transplant Infectious Disease (published online ahead of print). The incidence was 37.6 per 1,000 patient-years among African-American subjects. By comparison, the annual incidence in the general population is estimated to be 1.5-3.0 cases per 1,000 person-years.

Compared with white subjects, African Americans had a nearly twofold increased risk, the researchers reported.

Heart transplant recipients had the highest incidence of HZ—40.0 infections per 1,000 patient-years. Compared with kidney transplant recipients, heart transplant recipients had a 70% increased risk of HZ infection after adjusting for multiple potential confounders.

“To the best of our knowledge, this study is one of the largest multicenter cohort of SOT recipients to date to assess the incidence of HZ,” the authors noted. “These data provide important information on long-term risk of HZ following SOT, afford the first assessment of risk in other non-white populations, and present further evidence for an increased risk of HZ in SOT recipients.”

Dr. Pergam and his colleagues also pointed out that their study is the first to reveal a higher incidence of HZ in African-American SOT recipients. This higher incidence could be related to higher rates of organ rejection in this racial group, increased utilization of VA resources, differences in immunosuppressive regimens, or some other undetermined racial variations in viral immune response.

The incidence of HZ declined with time. Subjects who received their organ from 1996-1999, 2000-2004, and 2005-2007 had an incidence of 29.0, 19.1, and 15.2 per 1,000 patient-years, respectively.

The researchers hypothesize that the decreased incidence observed in latter cohorts is likely in part a result of shorter follow-up and increasing use of antiviral cytomegalovirus prophylaxis, which has been shown to further limit HZ risk.

Similar to the general population, the incidence was also highest among patients older than 55 years: 26.3 per 1,000 patient-years. By comparison, the incidence was 20.4 and 19.8 per 1,000 patient-years for patients younger than 45 and those aged 45-55 years.

UAB research: Preventing deaths from Herpes

"Herpes simplex virus infections that reach the central nervous system are a significant cause of mortality particularly among newborns. While use of acyclovir has improved outcomes, the number of fatalities and cases of permanent neurologic impairment is unacceptably high," said Debra C. Quenelle, PhD, Associate Professor, the University of Alabama at Birmingham School of Medicine. "CMX001 has demonstrated improved efficacy to acyclovir in reducing viral load and reducing viral replication, particularly in the CNS, in studies of Herpes Simplex Virus (HSV) infected mice which have been highly predictive of outcome in humans. Based on these promising results, CMX001 may have potential for use -- either alone or in combination - in the treatment of herpes encephalitis, neonatal herpes, or other severe HSV infections in humans."

California Jury Awards $2.4 Million for Herpes Infection

A Beverly Hills man has been hit with a $2.4 million judgment in a suit alleging that he negligently infected his soon-to-be-ex wife with genital herpes.

The suit highlights the unsettling prevalence of sexually transmitted diseases (STDs) and the ease with which they can be spread.



Read more: http://www.consumeraffairs.com/news04/2010/11/california-jury-awards-2-4-million-for-herpes-infection.html#ixzz15y4dlPOc

Herpes: Top Natural Supplements for Treatment

Herpes, one of the most common sexually transmitted diseases, is a virus that affects the mouth and the genital area appearing as sores that ooze and itch. Genital herpes can affect both men and women of any age and spreads through skin-to-skin contact. It does not spread through personal objects such as towels because the virus cannot survive outside the body.

Love, H Style Is the Ultimate Herpes and HPV Social Networking Community

Love, H Style is helping people worldwide increase awareness about genital herpes, oral herpes, genital warts, and HPV. The free social networking community also gives members a unique opportunity to express their feelings, share stories, date and encourage others in the same situation.

Vical to Update Herpes Simplex Vaccine Program at Keystone Conference

(GlobeNewswire via COMTEX) -- Vical Incorporated (VICL 2.26, +0.00, +0.01%) today announced that the company's Vice President of Clinical Development, Richard T. Kenney, M.D., is presenting preclinical results from the company's herpes simplex type 2 (HSV-2) vaccine program in a poster session Friday morning at the Keystone Symposium on Immunological Mechanisms of Vaccination (Seattle, October 27 -- November 1).

In Investigational Study, ZOSTAVAX®, Merck's Shingles Vaccine, Reduced Incidence of Shingles in Adults Ages 50 to 59 by Nearly 70

In a large clinical study of adults ages 50 to 59, ZOSTAVAX® (Zoster Vaccine Live), Merck's vaccine for the prevention of shingles (herpes zoster), reduced the incidence of shingles by nearly 70 percent (69.8) compared to placebo. These new data will be presented on Oct. 23 at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, British Columbia, Canada. Based on these results, earlier this year Merck filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for the use of ZOSTAVAX to prevent shingles in people 50 to 59 years of age.